Laurent-Puig P, Cugnenc P H
Service de Chirurgie Digestive, Oncologique et Générale, Hôpital Laënnec, Paris.
J Chir (Paris). 1997 Dec;134(7-8):279-82.
New technologies in molecular biology will allow the improvement of screening, diagnosis and prognosis of colorectal cancer patients. For example the determination of germline mutation in APC or in mismatch repair genes in patient with familial adenomatous polyposis or with HNPCC is now possible. The clinical surveillance can be restricted to the patients with these germline defects. More over the knowledge of somatic genetic alterations in colorectal cancer cells seems to be useful in the determination of prognosis of these patients or in order to predict the chemotherapy response.
分子生物学新技术将有助于改善结直肠癌患者的筛查、诊断和预后。例如，现在已经能够确定家族性腺瘤性息肉病或遗传性非息肉病性结直肠癌患者中APC基因或错配修复基因的种系突变。临床监测可以局限于有这些种系缺陷的患者。此外，了解结直肠癌细胞中的体细胞基因改变似乎有助于确定这些患者的预后或预测化疗反应。
